Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pfs25-IMX313 and Pfs48/45 Malaria Vaccines in Burkina Faso
NCT06549257Phase 2Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Jul 2025
- Primary completion
- Sep 2026
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Pfs25-IMX313 and Pfs48/45 in malaria (3 arms), sponsored by University of Oxford. Primary endpoint: Safety and reactogenicity of Pfs25-IMX313-Matrix-M, Pfs48/45-Matrix M administered alone or in combination at 8 months. Started Jul 2025; status: active, not recruiting.
02
Drugs
Pfs25-IMX313Pfs48/45
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06549257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06549257.